Items Tagged ‘Recurrent/Relapsed Rectal Cancer’

January 28th, 2016

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing

By

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no RAS mutations, or those with only the KRAS exon 2 mutation. These results were recently presented at the […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, KRAS exon 2, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, Stages I-III Rectal Cancer, vectibix


August 11th, 2015

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy

By

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers have announced that that drug has extended overall survival, the primary goal of the study. Vectibix is a targeted therapy that […]

View full entry

Tags: Colon Cancer, colorectal cancer, kras, metastatic colorectal cancer, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, vectibix, wild-type


March 17th, 2015

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer

By

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM  Colorectal cancer Immunotherapy Treatment Evaluation (“XCITE”), assesses XBiotech’s True Human™ monoclonal antibody (XilonixTM) for the treatment of […]

View full entry

Tags: Colon Cancer, colorectal cancer, immunotherapy, metastatic colorectal cance, monoclonal antibody, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xbiotech, xcite


February 19th, 2015

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer

By

The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium, January 15–17, in San Francisco, California.[1] According to estimates from the American Cancer Society, 93,090 cases of colon cancer and 39,610 cases of rectal cancer will be diagnosed in 2015. Colorectal […]

View full entry

Tags: advanced colorectal cancer, clinical trial, Colon Cancer, colon cancer treatment, colorectal cancer, crc, interleukin, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


January 16th, 2015

Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer

By

The results of an international phase III study evaluating 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy will be presented at the upcoming Gastrointestinal Symposium in San Francisco. The trial results suggest that a combination of the targeted drug Cyramza™ (ramucirumab) and FOLFIRI chemotherapy provides a survival advantage over […]

View full entry

Tags: Colon Cancer, colorectal cancer, cyramza, folfiri, News, ramucirumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


November 3rd, 2014

FOLFOXIRI + Bevacizumab Improves Outcomes for Metastatic Colorectal Cancer

By

According to a recent report in The New England Journal of Medicine, initial treatment with FOLFOXIRI plus Avastin® (bevacizumab), rather than FOLFIRI plus Avastin, improved progression-free survival in adults with inoperable metastatic colorectal cancer. According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about 40,000 new cases […]

View full entry

Tags: Colon Cancer, colorectal cancer, folfiri, folfoxiri, metastatic, metastatic colorectal cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


July 9th, 2014

TAS-102 Improves Survival in Advanced Colorectal Cancer

By

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.1 According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about […]

View full entry

Tags: Colon Cancer, colorectal cancer, crc, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, TAS-102


June 20th, 2014

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer

By

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or FOLFIRI) regimens led to a new benchmark median survival time of 29 months. The results presented as ASCO were from the […]

View full entry

Tags: asco, avastin, Colon Cancer, colorectal cancer, erbitux, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


March 5th, 2014

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer

By

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment success, according to two studies presented at the American Society of Clinical Oncology’s 2014 Gastrointestinal Cancers Symposium. Selective Internal Radiation […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


October 18th, 2013

Vectibix is Not Inferior to Erbitux in Wild-Type KRAS Metastatic Colorectal Cancer

By

Vectibix® (panitumumab) was non-inferior to Erbitux® (cetuximab) for overall survival in the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy, according to the results of a study presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Colorectal cancer remains the second leading […]

View full entry

Tags: Colon Cancer, News, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


May 29th, 2013

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases

By

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis, according to the results of a study published in the Journal of Clinical Oncology. Colorectal cancer remains the second leading cause of cancer-related death in the United States. Metastatic colorectal […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


November 6th, 2012

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers

By

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death in the United States. The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays a significant role in carcinogenesis. Approximately 15 to 20 […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, Stages I-III Rectal Cancer


August 15th, 2012

Zaltrap Approved for Metastatic Colorectal Cancer

By

The U.S. Food and Drug Administration (FDA) has approved Zaltrap® (ziv-aflibercept) for use in combination with the FOLFIRI chemotherapy regimen (folinic acid, fluorouracil, and ironotecan) to treat adults with metastatic colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related death in the United States. Metastatic colorectal cancer refers to cancer that has spread […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


January 19th, 2012

Regorafenib Shows Promise Against Metastatic Colorectal Cancer

By

The investigational drug regorafenib improves survival and delays cancer progression among patients with metastatic colorectal cancer that has worsened in spite of other treatments. These results will be presented at the 2012 Gastrointestinal Cancers Symposium. Colorectal cancer remains the second leading cause of cancer-related death in the United States. Metastatic colorectal cancer refers to cancer […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


February 16th, 2010

Preventive Treatment Reduces Skin Side Effects of Vectibix

By

Among patients with metastatic colorectal cancer treated with the targeted therapy Vectibix® (panitumumab), preventive skin care reduces the occurrence of skin side effects. These results were published in the Journal of Clinical Oncology. Colorectal cancer remains the second leading cause of cancer-related death in the United States. Metastatic colorectal cancer refers to cancer that has […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, Supportive Care